Antibody treatment for deadly skin infections

Researcher

Dr. Sarah Hobdey

Idaho Veterans Research and Education Foundation

Boise VA Medical Center

Status

In Review

Time remaining

Funding closed

Share this research:

social-facebook-box-blue-icon.png
twitter-icon.png
Linkedin-icon.png

Link copied!

About this study

Group A Streptococcus (GAS or Streptococcus pyogenes) is a bacteria that ranks among the top 10 causes of infection-associated death worldwide. Necrotizing soft tissue infections (NSTIs) are one of the most severe and life-threatening infections from this bacteria and lead to rapidly progressive death of skin and underlying tissue. Even with antibiotics and optimal care, one-quarter of NSTIs result in death. The major mechanism for this infection is through a toxin released by GAS. Through this study, we aim to engineer an antibody which will bind and effectively neutralize the GAS toxin thereby slowing or even progression of infection. We hope that this antibody could be given to infected patients along with standard antibiotics and supportive care to reduce death and disability.

Significance

Researcher's story

Contributions

-

-

-

loading.gif

-

funded

-

raised

-

goal

-

Subscribe to updates on this research

Favorite this research

Grant-based funding

Gift-based funding